RT Journal Article
SR Electronic
T1 National and subnational short-term forecasting of COVID-19 in Germany and Poland during early 2021
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.05.21265810
DO 10.1101/2021.11.05.21265810
A1 Bracher, Johannes
A1 Wolffram, Daniel
A1 Deuschel, Jannik
A1 Görgen, Konstantin
A1 Ketterer, Jakob L.
A1 Ullrich, Alexander
A1 Abbott, Sam
A1 Barbarossa, Maria V.
A1 Bertsimas, Dimitris
A1 Bhatia, Sangeeta
A1 Bodych, Marcin
A1 Bosse, Nikos I.
A1 Burgard, Jan Pablo
A1 Castro, Lauren
A1 Fairchild, Geoffrey
A1 Fiedler, Jochen
A1 Fuhrmann, Jan
A1 Funk, Sebastian
A1 Gambin, Anna
A1 Gogolewski, Krzysztof
A1 Heyder, Stefan
A1 Hotz, Thomas
A1 Kheifetz, Yuri
A1 Kirsten, Holger
A1 Krueger, Tyll
A1 Krymova, Elena
A1 Leithäuser, Neele
A1 Li, Michael L.
A1 Meinke, Jan H.
A1 Miasojedow, Błażej
A1 Michaud, Isaac J.
A1 Mohring, Jan
A1 Nouvellet, Pierre
A1 Nowosielski, Jedrzej M.
A1 Ozanski, Tomasz
A1 Radwan, Maciej
A1 Rakowski, Franciszek
A1 Scholz, Markus
A1 Soni, Saksham
A1 Srivastava, Ajitesh
A1 Gneiting, Tilmann
A1 Schienle, Melanie
YR 2022
UL http://medrxiv.org/content/early/2022/08/26/2021.11.05.21265810.abstract
AB Background During the COVID-19 pandemic there has been a strong interest in forecasts of the short-term development of epidemiological indicators to inform decision makers. In this study we evaluate probabilistic real-time predictions of confirmed cases and deaths from COVID-19 in Germany and Poland for the period from January through April 2021.Methods We evaluate probabilistic real-time predictions of confirmed cases and deaths from COVID-19 in Germany and Poland. These were issued by 15 different forecasting models, run by independent research teams. Moreover, we study the performance of combined ensemble forecasts. Evaluation of probabilistic forecasts is based on proper scoring rules, along with interval coverage proportions to assess forecast calibration. The presented work is part of a pre-registered evaluation study and covers the period from January through April 2021.Results We find that many, though not all, models outperform a simple baseline model up to four weeks ahead for the considered targets. Ensemble methods (i.e., combinations of different available forecasts) show very good relative performance. The addressed time period is characterized by rather stable non-pharmaceutical interventions in both countries, making short-term predictions more straightforward than in previous periods. However, major trend changes in reported cases, like the rebound in cases due to the rise of the B.1.1.7 (alpha) variant in March 2021, prove challenging to predict.Conclusions Multi-model approaches can help to improve the performance of epidemiological forecasts. However, while death numbers can be predicted with some success based on current case and hospitalization data, predictability of case numbers remains low beyond quite short time horizons. Additional data sources including sequencing and mobility data, which were not extensively used in the present study, may help to improve performance.Plain language summary The goal of this study is to assess the quality of forecasts of weekly case and death numbers of COVID-19 in Germany and Poland during the period of January through April 2021. We focus on real-time forecasts at time horizons of one and two weeks ahead created by fourteen independent teams. Forecasts are systematically evaluated taking uncertainty ranges of predictions into account. We find that combining different forecasts into ensembles can improve the quality of predictions, but especially case numbers proved very challenging to predict beyond quite short time windows. Additional data sources, in particular genetic sequencing data, may help to improve forecasts in the future.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJ. Bracher, M. Schienle and T. Gneiting acknowledge support from the Helmholtz Foundation via the SIMCARD Information and Data Science Pilot Project. T. Gneiting and D. Wolffram are grateful for support by the Klaus Tschira Foundation. D. Wolffram's contribution was moreover supported by the Helmholtz Association under the joint research school HIDSS4Health - Helmholtz Information and Data Science School for Health. N.I. Bosse was supported by the Health Protection Research Unit (grant code NIHR200908). S. Funk and S. Abbott were supperted by the Wellcome Trust (210758/Z/18/Z). The itwm-dSEIR forecasting team (J. Fiedler, N. Leith\"auser, J. Mohring) was supported by the Ministry of Health and Science of Rhineland Palatinate and the Fraunhofer Anti-Corona Program. S. Bhatia acknowledges funding from the Wellcome Trust (219415). Work on the ICM UW epidemiological model (J.M Nowosielski, M. Radwan, F. Rakowski) was supported by the Polish Minister of Science and Higher Education grant 51/WFSN/2020 given to the University of Warsaw. Development of the IMISE-SECIR model (Y. Kheifetz, H. Kirsten, S. Scholz) was funded in the framework of the project SaxoCOV (Saxonian COVID-19 Research Consortium). SaxoCOV was co-financed with tax funds on the basis of the budget passed by the Saxon state parliament. Model presentation was funded by the NFDI4Health Task Force COVID-19 (www.nfdi4health.de/task-force-covid-19-2) within DFG project LO-342/17-1.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study contains publicly available surveillance data on COVID-19 (from Robert Koch Institute, the Polish Ministry of Health and Johns Hopkins CSSE). These data used have been deposited at https://github.com/KITmetricslab/covid19-forecast-hub-deI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available at https://github.com/KITmetricslab/covid19-forecast-hub-de https://github.com/KITmetricslab/covid19-forecast-hub-de